Related Experiment Videos
Acyclic pyrazolo[3,4-d]pyrimidine nucleoside as potential leishmaniostatic agent
A Hasan1, M Satyanarayana, A Mishra
1Division of Medicinal & Process Chemistry, Central Drug Research Institute, Lucknow, India.
Nucleosides, Nucleotides & Nucleic Acids
|January 31, 2006
Summary
A novel pyrazolo[3,4-d]pyrimidine derivative (compound 4) effectively inhibits Leishmania donovani amastigotes in vitro and in vivo. This compound shows significant potential as an anti-leishmanial agent.
Area of Science:
- Medicinal Chemistry
- Parasitology
- Organic Synthesis
Background:
- Leishmania donovani causes visceral leishmaniasis, a neglected tropical disease.
- Existing treatments have limitations, necessitating the development of new anti-leishmanial drugs.
Purpose of the Study:
- To synthesize and evaluate a novel pyrazolo[3,4-d]pyrimidine derivative for anti-leishmanial activity.
- To compare the efficacy of the new compound with an iso-guanine analogue.
Main Methods:
- Chemical synthesis of 6-amino-1-hydroxyethoxymethyl-4 (5H)-oxopyrazolo[3,4-d]pyrimidine (compound 4).
- In vitro assessment of compound 4's inhibition against Leishmania donovani amastigotes.
- In vivo evaluation of compound 4's efficacy in a hamster model.
Main Results:
- Compound 4 demonstrated significant in vitro inhibition of Leishmania donovani amastigotes (89% at 30 microg/mL).
- Compound 4 showed superior efficacy compared to an iso-guanine analogue (52.8% inhibition at 100 microg/mL).
- In vivo studies in hamsters revealed a maximum inhibitory response of 94% against amastigote multiplication with compound 4.
Conclusions:
- The novel pyrazolo[3,4-d]pyrimidine derivative (compound 4) is a potent inhibitor of Leishmania donovani amastigotes.
- Compound 4 represents a promising lead candidate for the development of new anti-leishmanial therapies.